Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 610 KB, PDF-dokument

  • Fernando Valenzuela
  • Claudia De La Cruz
  • Cristóbal Lecaros
  • Javier Fernández
  • Gonzalo Hevia
  • Lara Valeska Maul
  • Thyssen, Jacob Pontoppidan
  • Cristián Vera-Kellet
  • Egeberg, Alexander
  • Daniela Armijo
  • Cristian Pizarro
  • Tatiana Riveros
  • Hernán Correa
  • Antonio Guglielmetti
  • Johannes A. Didaskalu
  • Jashin J. Wu
  • Christopher E.M. Griffiths
  • Ricardo Romiti
  • Julia Tatjana Maul

Background: Psoriasis is a chronic inflammatory skin disease associated with several important medical comorbidities. There are scant data available on the comorbidities of patients with psoriasis in South America. Aim: To examine the comorbidity profile of adult patients with psoriasis in Chile and its association with severity of psoriasis. Methods: This was a multicentre, cross-sectional study involving 16 hospitals and clinics in Chile, which used a 48-item questionnaire to study clinician- and patient-reported outcomes and comorbidities. Inferential analyses were performed by psoriasis severity, using Fisher exact test, Student t-test and multivariable logistic regression. Results: In total, 598 adult patients with psoriasis were included (51.1% male; mean age 49.2 ± 15.1 years); 48.5% mild and 51.4% moderate to severe; Psoriasis Area and Severity Index 11.6 ± 11.5; body surface area 14.7 ± 18.2%. Plaque psoriasis was the most common phenotype (90.2%), followed by guttate (13.4%). Psoriatic arthritis occurred in 27.3% of patients. Comorbidities were reported in 60.2% of all patients with psoriasis. Frequent concomitant diseases were obesity (25.3%), hypertension (24.3%), Type 2 diabetes mellitus (T2DM) (18.7%), dyslipidaemia (17.4%), metabolic syndrome (16.7%) and depression (14.4%). After adjustment, significant associations were found between moderate to severe psoriasis and obesity, T2DM and nonalcoholic fatty liver disease (NAFLD) compared with mild psoriasis. Conclusions: We report a large study of comorbidities, including depression, dyslipidaemia, T2DM and NAFLD, in people with psoriasis in Chile. The prevalence of comorbidities with psoriasis in Chile appears similar to that found in Western countries, and emphasizes the importance of assessing patients with psoriasis for risk factors for and presence of, comorbid disease in a multidisciplinary setting.

OriginalsprogEngelsk
TidsskriftClinical and Experimental Dermatology
Vol/bind47
Udgave nummer12
Sider (fra-til)2234-2241
Antal sider8
ISSN0307-6938
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We thank the dermatologists and patients who participated in this study as well as Pilar Valdes, Elba Gonzalez, Juan Honeyman and Rigoberto Parra. We acknowledge and are thankful for the collaboration with the Global Psoriasis Atlas (GPA), the International Psoriasis Council, the International Federation of Psoriasis Associations (IFPA) and the International League of Dermatological Societies (ILDA). The GPA's collaborating organizations in the establishment and organization of the GPA are: the IPC, the IFPA and the ILDS. We are grateful for the enthusiastic collaboration of all of the members of the GPA Board of Governors, Steering Committee and regional and national coordinators. Open access funding provided by Universitat Zurich.

Funding Information:
We thank the dermatologists and patients who participated in this study as well as Pilar Valdes, Elba Gonzalez, Juan Honeyman and Rigoberto Parra. We acknowledge and are thankful for the collaboration with the Global Psoriasis Atlas (GPA), the International Psoriasis Council, the International Federation of Psoriasis Associations (IFPA) and the International League of Dermatological Societies (ILDA). The GPA's collaborating organizations in the establishment and organization of the GPA are: the IPC, the IFPA and the ILDS. We are grateful for the enthusiastic collaboration of all of the members of the GPA Board of Governors, Steering Committee and regional and national coordinators. Open access funding was provided by the University of Zurich (Universitat Zurich).

Publisher Copyright:
© 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

ID: 341059425